Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/171601
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cuyàs, Elisabet | - |
dc.contributor.author | Buxó, Maria | - |
dc.contributor.author | Ferri Iglesias, Maria José | - |
dc.contributor.author | Verdura, Sara | - |
dc.contributor.author | Pemas, Sonia | - |
dc.contributor.author | Dorca, Joan | - |
dc.contributor.author | Álvarez, Isabel | - |
dc.contributor.author | Martínez, Susana | - |
dc.contributor.author | Pérez García, José Manuel | - |
dc.contributor.author | Batista López, Norberto | - |
dc.contributor.author | Rodríguez Sánchez, César A. | - |
dc.contributor.author | Amillano, Kepa | - |
dc.contributor.author | Domínguez, Severina | - |
dc.contributor.author | Luque, María | - |
dc.contributor.author | Morilla, Idoia | - |
dc.contributor.author | Stradella, Agostina | - |
dc.contributor.author | Vinas, Gemma | - |
dc.contributor.author | Cortés, Javier | - |
dc.contributor.author | Joven, Jorge | - |
dc.contributor.author | Brunet, Joan | - |
dc.contributor.author | López Bonet, Eugeni | - |
dc.contributor.author | García, Margarita | - |
dc.contributor.author | Saidani, Samiha | - |
dc.contributor.author | Queralt Moles, Xavier | - |
dc.contributor.author | Martin Castillo, Begoña | - |
dc.contributor.author | Menendez, Javier A. | - |
dc.date.accessioned | 2020-10-29T08:11:49Z | - |
dc.date.available | 2020-10-29T08:11:49Z | - |
dc.date.issued | 2019-01-01 | - |
dc.identifier.uri | http://hdl.handle.net/2445/171601 | - |
dc.description.abstract | Background: The minor allele (C) of the single-nucleotide polymorphism (SNP) rs11212617, located near the ataxia telangiectasia mutated (ATM) gene, has been associated with an increased likelihood of treatment success with metformin in type 2 diabetes. We herein investigated whether the same SNP would predict clinical response to neoadjuvant metformin in women with early breast cancer (BC). Methods: DNA was collected from 79 patients included in the intention-to-treat population of the METTEN study, a phase 2 clinical trial of HER2-positive BC patients randomized to receive either metformin combined with anthracycline/taxane-based chemotherapy and trastuzumab or equivalent regimen without metformin, before surgery. SNP rs11212617 genotyping was assessed using allelic discrimination by quantitative polymerase chain reaction. Results: Logistic regression analyses revealed a significant relationship between the rs11212617 genotype and the ability of treatment arms to achieve a pathological complete response (pCR) in patients (odds ratio [OR](genotypexarm) = 10.33, 95% confidence interval [CI]: 1.29-82.89, p = 0.028). In the metformin-containing arm, patients bearing the rs11212617 C allele had a significantly higher probability of pCR (ORA/C,C/C = 7.94, 95% CI: 1.60-39.42, p = 0.011). Conversely, no association was found between rs11212617 and clinical response in the reference arm (ORA/C,C/C = 0.77, 95% CI: 0.20-2.92, p = 0.700). After controlling for tumor size and hormone receptor status, the rs11212617 C allele remained a significant predictor of pCR solely in the metformin-containing arm. Conclusions: If reproducible, the rs11212617 C allele might warrant consideration as a predictive clinical biomarker to inform the personalized use of metformin in BC patients. | - |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Frontiers Media Sa | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3389/fonc.2019.00193 | - |
dc.relation.ispartof | Frontiers In Oncology, 2019-01-01, Vol. 9 num. 193 | - |
dc.relation.uri | https://doi.org/10.3389/fonc.2019.00193 | - |
dc.rights | cc by (c) Cuyàs, Elisabet et al., 2019 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Càncer de mama | - |
dc.subject.classification | Marcadors bioquímics | - |
dc.subject.classification | Assaigs clínics | - |
dc.subject.other | Breast cancer | - |
dc.subject.other | Biochemical markers | - |
dc.subject.other | Clinical trials | - |
dc.title | The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2020-10-26T09:24:45Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 30984619 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
CuyasE.pdf | 1.57 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License